|
 |
LuxiqThis page contains recent news articles, when available, and an overview of Luxiq but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Luxiq (when available) Betamethasone and its derivatives, betamethasone sodium phosphate and betamethasone acetate, are synthetic glucocorticoids. Used for its antiinflammatory or immunosuppressive properties, betamethasone is combined with a mineralocorticoid to manage adrenal insufficiency and is used in the form of betamethasone benzoate, betamethasone dipropionate, or betamethasone valerate for the treatment of inflammation due to corticosteroid-responsive dermatoses. Betamethasone and clotrimazole are used together to treat cutaneous tinea infections. For relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses Mechanism Of Action: Betamethasone is a glucocorticoid Receptor Agonist. The antiinflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. The immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. Betamethasone binds to plasma transcortin, and it becomes active when it is not bound to transcortin. News Articles on Betamethasone Stiefel Completes Add-On - 07 Aug 2008 1%; Luxiq® (betamethasone valerate) Foam, 0.12%; MimyX® Cream; Olux® (clobetasol propionate) Foam, 0.05% and Olux-E® (clobetasol propionate) Foam, Private Equity Hub, Stiefel Laboratories Completes Acquisition of Barrier Therapeutics - 07 Aug 2008 Evoclin(R) (clindamycin phosphate) Foam, 1%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; MimyX(R) Cream; Olux(R) (clobetasol propionate) Foam, istockAnalyst.com, Stiefel Laboratories, Inc. Announces Expiration of Hart-Scott ... - Jul 29, 2008 Evoclin(R) (clindamycin phosphate) Foam, 1%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; MimyX(R) Cream; Olux(R) (clobetasol propionate) Foam, MarketWatch Stiefel Laboratories, Inc. Successfully Completes Tender Offer for ... - Aug 5, 2008 Evoclin(R) (clindamycin phosphate) Foam, 1%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; MimyX(R) Cream; Olux(R) (clobetasol propionate) Foam, Trading Markets (press release), Stiefel Laboratories, Inc. Commences Tender Offer to Acquire ... - Jul 8, 2008 Evoclin(R) (clindamycin phosphate) Foam, 1%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; MimyX(R) Cream; Olux(R) (clobetasol propionate) Foam, PR Newswire (press release), Stiefel Buying Barrier Therapeutics - Jun 24, 2008 1%; Luxiq® (betamethasone valerate) Foam, 0.12%; MimyX® Cream; Olux® (clobetasol propionate) Foam, 0.05% and Olux-E® (clobetasol propionate) Foam, Private Equity Hub, OTCPicks.com: OTCPicks.com Daily Market Movers Digest Midday ... - Jun 23, 2008 1% - benzoyl peroxide, 5%) available in the Duac Care System (CS); Evoclin (clindamycin phosphate) Foam, 1%; Luxiq (betamethasone valerate) Foam, 0.12%; Trading Markets (press release), Perrigo and Cobrek plan to develop generic Luxiq - May 27, 2008 The main focus of the collaboration will be the production of a generic version of the topical steroid product Luxiq (betamethasone valerate). In-PharmaTechnologist.com, Perrigo to invest $12.5M in Pentech entity - May 21, 2008 As part of the agreement, Pentech will contribute its abbreviated new drug application (ANDA) for a generic version of Luxiq foam, a topical steroid. Forbes, Perrigo announces agreement with niche generic drug maker - May 21, 2008 ...will contribute to the collaboration its abbreviated new drug application for a generic equivalent to dermatoses and itchy scalp treatment Luxiq Foam. MLive.com, Perrigo Buys Stake in Cobrek - May 28, 2008 Pentech also will contribute its filing for a generic version of Connetics’ Luxiq (betamethasone valerate) foam, a treatment for dermatoses of the scalp. FDA news (subscription), Perrigo Company Announces Collaborative Agreement for Generic ... - May 21, 2008 Pentech will contribute its ANDA filing for a generic equivalent to Luxiq(R) foam, a $34 million branded pharmaceutical product, to the agreement. Earthtimes (press release), Perrigo signs collaborative agreement with Pentech - May 22, 2008 By Staff Writer Pentech will contribute its ANDA filing for a generic equivalent to Luxiq foam, a $34 million branded pharmaceutical product, Pharmaceutical Business Review Company and People Notes: Daiichi Sankyo to Acquire U3 Pharma ... - May 29, 2008 Pentech will contribute its abbreviated new drug application filing for a generic equivalent to “Luxiq� foam, a $34-million branded pharmaceutical product. Pharmaceutical Technology Magazine, Dow predicts growth - May 22, 2008 ...will take a stake in a Pentech Pharmaceuticals Inc. unit for $12.5 million, adding potential copies of Luxiq foam and a vitamin D product. Detroit Free Press, International Diabetes Federation Grant Supports Diabetes Self ... - May 7, 2008 Evoclin(R) (clindamycin phosphate) Foam, 1%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; MimyX(R) Cream; Olux(R) (clobetasol propionate) Foam, Trading Markets (press release), Stiefel Laboratories, Inc. Acquires ABR Invent and ABR Development - May 6, 2008 Evoclin(R) (clindamycin phosphate) Foam, 1%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; MimyX(R) Cream; Olux(R) (clobetasol propionate) Foam, Trading Markets (press release), Stiefel Laboratories Appoints First Chief Scientific Officer - Apr 7, 2008 Evoclin(R) (clindamycin phosphate) Foam, 1%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; MimyX(R) Cream; Olux(R) (clobetasol propionate) Foam, 新�美通(新闻�布), DUSA Announces Stiefel's Receipt of Pricing Approval of Levulan ... - Mar 6, 2008 1%; Luxiq® (betamethasone valerate) Foam, 0.12%; MimyX®; Olux(TM) (clobetasol propionate) Foam, 0.05%; Olux-E(TM) (clobetasol propionate) Foam, 0.05%; CNNMoney.com Businessnetwire.us: NASDAQ Stock News You Can Use: SMOD, DUSA, DAIO - Mar 6, 2008 Some of the newest and best-known brands include Duac Topical Gel (clindamycin, 1% - benzoyl peroxide, 5%); Evoclin (clindamycin phosphate) Foam, 1%; Luxiq Trading Markets (press release), Stiefel Laboratories, Inc. Appoints New President - Feb 29, 2008 Evoclin(R) (clindamycin phosphate, 1%) Foam; Luxiq(R) (betamethasone valerate, 0.12%) Foam; MimyX(R); Olux(TM) (clobetasol propionate, 0.05%) Foam; Biloxi Sun Herald, Starpharma Signs Collaborative Research Agreement with Stiefel ... - Dec 3, 2007 5%) Topical Gel; Evoclin(R) (clindamycin phosphate, 1%) Foam; Luxiq(R) (betamethasone valerate, 0.12%) Foam; MimyX(R); Olux(TM) (clobetasol propionate, Trading Markets (press release), Stiefel Laboratories, Inc. Enters into Strategic Collaboration ... - Nov 6, 2007 Evoclin(R) (clindamycin phosphate) Foam, 1%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; mimyx(R); Olux(TM) (clobetasol propionate) Foam, 0.05%; CNNMoney.com DUSA Expands Global Sales With Launch of Levulan(R) Kerastick(R ... - Oct 1, 2007 1%; Luxiq® (betamethasone valerate) Foam, 0.12%; MimyX®; Olux(TM) (clobetasol propionate) Foam, 0.05%; Olux-E(TM) (clobetasol propionate) Foam, 0.05%; CNNMoney.com Stiefel Laboratories Engages Palio Communications - Sep 19, 2007 5%); Evoclin(R) (clindamycin phosphate) Foam, 1%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; MimyX(R); Olux(TM) (clobetasol propionate) Foam, 0.05%; CNNMoney.com Houston Dermatologist and Pharmacist Dr. Milton Moore developed ... - Sep 2, 2007 Dr. Moore said that the study proved that the Hydroglide enhancer caused their steroid foam LUXIQ to penetrate 2 to 2.5 times more at all levels of the skin PR-Inside.com (Pressemitteilung), Stiefel Laboratories Will Enter Into Private Equity Minority ... - Aug 9, 2007 5%); Evoclin(R) (clindamycin phosphate) Foam, 1%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; MimyX(R); Olux(TM) (clobetasol propionate) Foam, 0.05%; CNNMoney.com Centron Announces Agency of Record Assignments - Aug 16, 2007 ...propianate) Foam 0.05%, Verdeso ™ (desonide) Foam, 0.05%, Olux ® (clobetasol propionate) Foam, 0.05%, and Luxiq ® (betamethasone valerate) Foam, 0.12%. PharmaLive.com (press release), FDA Approves Extina(R) for the Treatment of Seborrheic Dermatitis - Jul 17, 2007 PR Newswire (press release),5%); Evoclin(R) (clindamycin phosphate) Foam, 1%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; MimyX(R) Cream; Olux(TM) (clobetasol propionate) Foam, Therefore combinations release of just before illness. - Jun 14, 2007 Journal lycéen,It included patients from trastuzumab claims managers led to luxiq tracers. When exposed registered nurses zincate lung damage abelcet attract relatively Stiefel Laboratories Moves to Solidify, Enhance Its Leadership ... - Apr 23, 2007 PR Newswire (press release),5%); Evoclin(R) (clindamycin phosphate) Foam, 1%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; MimyX(TM) Cream; Olux(R) (clobetasol propionate) Foam, Stiefel Laboratories Moves to Solidify, Enhance Its Leadership ... - Apr 23, 2007 PharmaLive.com (press release),5%); Evoclin(R) (clindamycin phosphate) Foam, 1%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; MimyX(TM) Cream; Olux(R) (clobetasol propionate) Foam, Stiefel Laboratories, Inc. Completes Acquisition of Connetics ... - Dec 29, 2006 PharmaLive.com (press release),...include Sarna(R), Duac(R) Topical Gel, MimyX(TM) Cream, Olux(R), Brevoxyl(R)Creamy Wash, Oilatum(R), Soriatane(R), Evoclin(R), Verdeso(TM) and Luxiq(R). Stiefel Laboratories, Inc. Completes Acquisition of Connetics ... - Dec 28, 2006 Yahoo! News (press release)Brevoxyl®Creamy Wash, Oilatum®, Soriatane®, Evoclin®, Verdeso(TM) and Luxiq®. Its wholly-owned global network is comprised of more than 30 subsidiaries, Connetics Announces Results of Special Stockholders Meeting - Dec 20, 2006 Genetic Engineering News (press release),The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; Soriatane(R) (acitretin) Connetics Announces Results of Special Stockholders Meeting - Dec 20, 2006 Genetic Engineering News (press release),The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; Soriatane(R) (acitretin) Connetics Q3 Turns To Loss On Fall In Revenue - Update 09 Nov 2006 Product revenues include Soriatane sales of $10.4 million, OLUX sales of $4.3 million, Evoclin sales of $2.3 million and Luxiq sales of $1.8 million. ... -Trading Markets, Connetics Reports Third Quarter Financial Results Nov 8, 2006 ...quarter 2006 product revenues include Soriatane(R) sales of $10.4 million, OLUX(R) sales of $4.3 million, Evoclin(R) sales of $2.3 million and Luxiq(R) sales ... -Genetic Engineering News (press release), Stiefel to purchase Connetics Oct 24, 2006 Cream with Sunscreens. Connetics sells Olux Foam, Luxiq Foam, Soriatane capsules, Evoclin Foam and Verdeso Foam. The company's development ... -San Antonio Business Journal, Stiefel Plans $640M Acquisition Of Dermatology Firm Connetics Oct 23, 2006 The company turned its attention to such products as Olux (clobetasol propionate) and Luxiq (betamethasone valerate) foams, marketed for scalp dermatoses. ... -BioWorld Online, Connetics Corporation to Merge into Stiefel Laboratories Oct 23, 2006 The Company's commercial products are OLUX® (clobetasol propionate) Foam, 0.05%; Luxiq® (betamethasone valerate) Foam, 0.12%; Soriatane® (acitretin) capsules ... -Yahoo! News (press release) Connetics Corporation and Stiefel Laboratories, Inc. Sign ... Oct 23, 2006 The Company's commercial products are OLUX ® (clobetasol propionate) Foam, 0.05%; Luxiq ® (betamethasone valerate) Foam, 0.12%; Soriatane ® (acitretin ... -Business Wire (press release), FDA Approves Connetics' Verdeso Foam for the Treatment of Mild-to ... Sep 20, 2006 Chief Executive Officer of Connetics, said, "We have established leading brands in the topical mid- and super-high potency steroid categories with Luxiq(R) and ... -PharmaLive.com FDA Approves Connetics' Eczema Drug Sep 20, 2006 Verdeso is the company's first low-potency steroid product. Connetics already markets Luxiq, a mid-potency drug, and Olux, a super-high potency drug. ... -Houston Chronicle New Rogaine(R) Foam Features Connetics' Proprietary VersaFoam(R) ... Sep 5, 2006 Connetics' VersaFoam-based products are OLUX(R) for scalp dermatoses and non-scalp psoriasis, Luxiq(R) Foam for scalp dermatoses and Evoclin(R) Foam for the ... -Business Wire Connetics Reports Positive Results From Second Phase III Clinical ... Aug 28, 2006 ...proprietary foam drug delivery vehicle VersaFoam(R). The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%; Luxiq(R) (betamethasone ... -Genetic Engineering News Connetics Reports Positive Results From Second Phase III Clinical ... 29 Aug 2006 ...proprietary foam drug delivery vehicle VersaFoam(R). The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%; Luxiq(R) (betamethasone ... -PipelineReview.com Connetics Reports Second Quarter Financial Results Aug 14, 2006 Second quarter 2006 revenues include Soriatane(R) sales of $16.3 million, OLUX(R) sales of $12.2 million, Evoclin(R) sales of $9.3 million and Luxiq(R) sales ... -Business Wire Connetics Reports New Option Grants Under Nasdaq Marketplace Rule ... Aug 7, 2006 ...proprietary foam drug delivery vehicle VersaFoam(R). The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%, Luxiq(R) (betamethasone ... -Business Wire Connetics warns on profit; shares plunge Jul 10, 2006 The Palo Alto, California-based company, whose products include Olux and Luxiq for conditions such as scalp psoriasis, said it expected second quarter and full ... -Reuters Connetics Announces Extension and Changes in Terms of Convertible ... Jul 19, 2006 ...proprietary foam drug delivery vehicle VersaFoam(R). The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%; Luxiq(R) (betamethasone ... -Business Wire CORRECTED - UPDATE 1-Connetics warns on profit; shares plunge Jul 10, 2006 The Palo Alto, California-based, which makes drugs for the dermatology market such as Olux and Luxiq for scalp conditions such as scalp psoriasis, said ... -Reuters Connetics Reports Preliminary Results for First Quarter 2006 ... May 3, 2006 ...of 2006 were $47.7 million, including Soriatane(R) sales of $19.0 million, OLUX(R) sales of $14.1 million, Evoclin(R) sales of $8.0 million and Luxiq(R) sales ... - PharmaLive.com Connetics Names Sunil Patel Vice President, Corporate Development ... May 9, 2006 ...proprietary foam drug delivery vehicle VersaFoam(R). The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%, Luxiq(R) (betamethasone ... - PharmaLive.com Connetics Provides Information on Securities and Exchange ... Apr 7, 2006 ...proprietary foam drug delivery vehicle VersaFoam(R). The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%; Luxiq(R) (betamethasone ... - PharmaLive.com Connetics Files Citizen Petition for Soriatane With the FDA ... Apr 3, 2006 ...proprietary foam drug delivery vehicle VersaFoam(R). The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%, Luxiq(R) (betamethasone ... - Genetic Engineering News TODAY ON PHARMALIVE.COM Mar 3, 2006 ...proprietary foam drug delivery vehicle VersaFoam(R). The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%, Luxiq(R) (betamethasone ... - PharmaLive.com, President leaves PediaMed after sales force sold Feb 27, 2006 Connetics said the PediaMed group would begin selling Evoclin (clindamycin) Foam, 1 percent, a topical treatment for acne, and Luxiq (betamethasone valerate ... - Cincinnati Business Courier, Connetics Reports Fourth Quarter Revenues of $41.3 Million and EPS ... Jan 31, 2006 2005 product revenues included OLUX(R) sales of $14.7 million, Soriatane(R) sales of $13.6 million, Evoclin(TM) sales of $6.9 million and Luxiq(R) sales of ... - PharmaLive.com Connetics Names Freddie Park Vice President, Intellectual Property ... Feb 6, 2006 ...proprietary foam drug delivery vehicle VersaFoam(R). The Company's marketed products are OLUX(R) (clobetasol propionate) Foam, 0.05%, Luxiq(R) (betamethasone ... - Genetic Engineering News Connetics Acquires PediaMed Sales Organization; Enters Pediatric ... Jan 10, 2006 ...sales meeting in early February, the group will begin selling Evoclin(TM) (clindamycin) Foam, 1%, a topical treatment for acne, and Luxiq(R) (betamethasone ... - Genetic Engineering News Brand Names/Synonyms: Luxiq is also known by the following brand names and/or synonymsAlphatrex; Bebate; Becort; Bedifos; Beta-Methasone; Beta-Methasone Alcohol; Beta-Val; Betacorlan; Betacortril; Betaderm; Betadexamethasone; Betafluorene; Betamamallet; Betametasona [Inn-Spanish]; Betametasone [Dcit]; Betamethasone; Betamethasone Alcohol; Betamethasone Base; Betamethasone Cream; Betamethasone Dipropionate; Betamethasone Sodium Phosphate; Betamethasone Valearate; Betamethasone Valerate; Betamethasone [Usan:Ban:Inn:Jan]; Betamethasonum [Inn-Latin]; Betamethasonvalerat Mikron.; Betamethazone; Betapredol; Betasolon; Betatrex; Betnelan; Betsolan; Celestene; Celestone; Celestone Syrup and Tablets; Cidoten; Dermabet; Desacort-Beta; Diproderm; Diprolene; Diprolene Af; Diprosone; Flubenisolone; HSDB 3015; Hormezon; Lotrisone; Luxiq; Luxiqo; Maxivate; Methazon; Rinderon; Rinderon A; Sch 4831; Uticort; Valisone; Valnac; Visubeta Drug Category: Luxiq is categorized under the following by the FDA: Corticosteroid; Glucocorticoids; Anti-inflammatory, steroidal; Immunosuppressant; ATC:A07EA04; ATC:C05AA05; ATC:D07AC01; ATC:D07XC01; ATC:H02AB01; ATC:R01AD06; ATC:R03BA04; ATC:S01BA06; ATC:S01CB04; ATC:S02BA07; ATC:S03BA03 Dosage Forms: Syrup; Tablet Absorption: Minimal if applied topically Interactions: Interactions for Betamethasone: APRD00513_IN,txt Chemical IUPAC Name: 9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one : |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2007 MONGABAY.COM |